Intelligence · Patents
Patents expiring in 2041
Annual patent cliff calendar for 2041 — US pharmaceutical patents by expiration date.
- Patents
- 2,000
Quick answer
2,000 indexed pharmaceutical patents have expiration dates in 2041. Browse by soonest expiry with links to assignee companies and related drugs.
-
US 11046650
Deuterated compounds and uses thereof
granted -
US 11045504
Compositions and methods for treatment of cancer using bacteria
granted -
US 11046670
Piperazinyl norbenzomorphan compounds and methods for using the same
granted -
US 11045493
Synthetic melanin nanoparticles and uses thereof
granted -
US 11045558
RPGR gene therapy for retinitis pigmentosa
granted -
US 11046755
Antibody based reagents that specifically recognize toxic oligomeric forms of tau
granted -
US 11046649
Compounds useful as inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan dioxygenase
granted -
US 11046691
2-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors
granted -
US 11045453
Serine protease inhibitor for treating coronavirus infection
granted -
US 11045425
Method of encapsulating pancreatic islet cells introduced to siRNA against PHLDA3
granted -
US 11046690
Pyridazinones and methods of use thereof
granted -
US 11045443
Glutaminase inhibitor therapy
granted -
US 11045448
Piperidines as covalent menin inhibitors
granted -
US 11045461
Compositions of CXCR4 inhibitors and methods of preparation and use
granted -
US 11046703
Small molecule MDM2 protein degraders
granted -
US 11046701
Salt of cetagliptin, preparation method thereof, pharmaceutical composition, and use thereof
granted -
US 11046710
Sulfonamide compounds
granted -
US 11046709
Fused 1,4-diazepines as BET bromodomain inhibitors
granted -
US 11046730
Antimicrobial compositions
granted -
US 11046759
Matrix metalloprotease-cleavable and serine protease-cleavable substrates and methods of use thereof
granted -
US 11046946
PEGylated L-asparaginase
granted -
US 11046769
Multispecific binding constructs against checkpoint molecules and uses thereof
granted -
SG 11202104918P
THERAPY FOR TREATING CANCER WITH AN INTRATUMORAL AND/OR INTRAVENOUS ADMINISTRATION OF A RECOMBINANT MVA ENCODING 4-1BBL (CD137L) AND/OR CD40L
granted -
US 11046941
Methods of generating nucleic acid fragments
granted -
US 11046959
Compositions comprising TALENs and methods of treating HIV
granted -
US 11046785
Compositions and methods for treatment of diabetic macular edema
granted -
US 11045457
Piperidinyl-3-(aryloxy)propanamides and propanoates
granted -
US 11045478
Salts of potassium ATP channel openers and uses thereof
granted -
US 11045472
Quinazoline-pyridine derivatives for the treatment of cancer-related disorders
granted -
US 11045466
Parenteral formulations of lipophilic pharmaceutical agents and methods for preparing and using the same
granted -
US 11045549
Pharmaceutical compositions comprising meloxicam
granted -
US 11045482
Use of glucocorticoid receptor modulators in the treatment of catecholamine-secreting tumors
granted -
US 11052103
Patatin-like phospholipase domain containing 3 (PNPLA3) iRNA compositions and methods of use thereof
granted -
US 11052123
Method of obtaining olive oil and extracts from olives
granted -
US 11052057
Use of cysteamine and derivatives thereof to suppress tumor metastases
granted -
US 11052064
Compositions, methods and systems for the treatment of cutaneous disorders
granted -
US 11052073
Sphingosine kinase 2 inhibitor for treating coronavirus infection
granted -
US 11052075
Pharmaceutical compositions of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid and administration thereof
granted -
US 11052144
Methods of tumor vaccination
granted -
US 11053262
Heterocyclic amide compounds having RORyT inhibitory action
granted -
US 11053310
Antibodies for the treatment of cancers
granted -
US 11053314
Methods to eliminate cancer stem cells by targeting CD47
granted -
US 11052116
Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
granted -
US 11052157
Enhanced loading of intact, bacterially derived vesicles with small molecule compounds
granted -
US 11052118
Enhanced stem cell composition
granted -
US 11053242
[9,10-dimethoxy-3-(2-methylpropyl)-1H,2H,3H,4H,6H,7H,11BH-pyrido-[2,1-a]isoquinolin-2-yl]methanol and compounds, compositions and methods relating thereto
granted -
US 11053213
Pharmaceutical compounds
granted -
US 11053261
Solid state forms of ixazomib citrate
granted
Frequently asked questions
How many pharma patents expire in 2041?
2,000 published patents in our USPTO index have expiration dates falling in calendar year 2041.